Home / News / Invectys publications

Invectys publications

HLA-G Neo-Expression on Tumors

Loustau M, Anna F, Dréan R, Lecomte M, Langlade-Demoyen P, Caumartin J.

Frontiers in Immunology 2020

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm

Bôle-Richard E, Fredon M, Biichlé S, Anna F, Certoux J-M, Renosi F, Tsé F, Molimard C, Valmary-Degano S, Jenvrin A, Warda W, Pallandre J-R, BonnefoyF , Poussard M, Deschamps M, Petrella T, Roumier C, Macintyre E, Féger F, Brissot E, Mohty M, HoWangYin K-Y, Langlade-Demoyen P, Loustau M, Caumartin J, Godet Y, Binda D, Pagadoy M, Deconinck E, Daguindau E, Saas P, Ferrand C, Angelot-Delettre F, Adotévi O, Garnache-Ottou F.

Leukemia 2020

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors

Teixeira L, Medioni J, Garibal J, Adotévi O, Doucet L, Dragon Durey M-A, Ghrieb Z, Kiladjian J-J, Brizard M, Laheurte C, Wehbe M, Pliquet E, Escande E, Defrance R, Culine S, Oudard SM, Wain-Hobson S, Doppler V, Huet T, Langlade-Demoyen P.

Clinical Cancer Research 2019, CCR-19-1614

A DNA telomerase vaccine for canine cancer immunotherapy

Thalmensi J, Pliquet E, Liard C, Chamel G, Kreuz C, Bestetti T, Escande M, Kostrzac A, Pailhes-Jimenez AS, Bourges E, Julithe M, Bourre L, Keravel O, Clayette P, Huet T, Wain-Hobson S, Langlade-Demoyen P.

Oncotarget 2019; 10:3361-3372

Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46 mice.

Pliquet E, Ruffie C, Escande M, Thalmensi J, Najburg V, Combredet C, Bestetti T, Julithe M, Liard C, Huet T, Wain-Hobson S, Tanguy F, Langlade-Demoyen P.

Anti-cancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response.

Thalmensi J, Pliquet E, Liard C, Escande M, Bestetti T, Julithe M et al. OncoImmunology.

Optimization of a gene electrotransfer procedure for efficient intradermal immunization with an hTERT-based DNA vaccine in mice.

Calvet CY, Thalmensi J, Liard C, Pliquet E, Bestetti T, Huet T, Langlade-Demoyen P, Mir LM.

Mol Ther Methods Clin Dev. 2014 Sep 24;1:14045. doi: 10.1038/mtm.2014.45. eCollection 2014.

APOBEC3A catabolism of electroporated plasmid DNA in mouse muscle.

Kostrzak A, Henry M, Langlade-Demoyen P, Wain-Hobson S, Vartanian JP.

Gene Ther. 2015 Jan;22(1):96-103.

Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.

Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotévi O.
Clin Cancer Res. 2012 Nov 15;18(22):6284-95.

Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.

Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillère B, Tartour E, Borg C, Adotévi O.
Clin Cancer Res. 2012 May 15;18(10):2943-53.

Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.

Rusakiewicz S, Dosset M, Mollier K, Souque P, Charneau P, Wain-Hobson S, Langlade-Demoyen P, Adotévi O.
Vaccine. 2010 Aug 31;28(38):6374-81.

Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.

Adotévi O, Mollier K, Neuveut C, Dosset M, Ravel P, Fridman WH, Tartour E, Charneau P, Wain-Hobson S, Langlade-Demoyen P.
Blood. 2010 Apr 15;115(15):3025-32.